Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

161. Atomoxetine for ADHD - horizon scanning review

Atomoxetine for ADHD - horizon scanning review Atomoxetine for ADHD - horizon scanning review Atomoxetine for ADHD - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Atomoxetine for ADHD - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). New and Emerging Technology Briefing (...) . 2001 Authors' objectives To summarise the current research evidence on atomoxetine for attention deficit hyperactivity disorder (ADHD). Authors' conclusions - Clinical impact: There is likely to be a significant clinical impact from the introduction of atomoxetine due to the fact that it will be the first non-stimulant drug therapy licensed for the treatment of ADHD. - Service impact: Although there is unlikely to be a significant service impact with the introduction of atomoxetine for people

2001 Health Technology Assessment (HTA) Database.

162. The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD)

The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD) The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD) The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD) Smith B H, Waschbusch D A, Willoughby M T, Evans S Authors' objectives To review studies of interventions for adolescents diagnosed (...) with attention-deficit/hyperactivity disorder (ADHD) in order to evaluate the efficacy of the interventions. Searching MEDLINE, ERIC and PsycLIT were searched using the following keywords: 'treatment', 'adolescent', 'teen', 'ADHD', 'hyperactive', 'inattentive', and 'stimulant'. Further studies were identified from references in the review papers. No restrictions on publication language were reported. Study selection Study designs of evaluations included in the review Empirical studies were included. Specific

2000 DARE.

163. Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood

Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation National Institute for Clinical Excellence. Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 13. 2000 Authors' objectives To provide guidance on the use of methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood. Authors' conclusions Guidance 1.1 Methylphenidate is recommended for use as part

2000 Health Technology Assessment (HTA) Database.